Hi @wombat777.
Thank you for your analysis.
You rate a 50% success for AML.
Given the historical success of bisantrene coupled with the recent successful trial in Israel, what are the main outstanding risks that you see remain for Pillar 3?
Is it the risk that the IND will not be approved, and hence no FDA approval?
Or do you think most of the risk is weighted on the clinical side (perhaps unlikely given good historical results)?
Assuming IND is approved, what do you think the success rate would be for pillar 3?
Cheers!
MST valuation of RAC, page-32
-
- There are more pages in this discussion • 265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.62 |
Change
0.015(0.93%) |
Mkt cap ! $276.0M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $456.4K | 284.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 2659 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |